Eris Lifesciences Limited has reported strong financial growth for the year ended March 31, 2026. The Board of Directors has approved the audited financial results and declared an interim dividend of ₹7.21 per share (721%) for the 2026-27 financial year. The company recorded an annual consolidated net profit of ₹647.51 crore, reflecting a robust operational performance and strategic expansion across its pharmaceutical business segments.
Financial Performance Highlights
For the financial year ended March 31, 2026, Eris Lifesciences reported a consolidated total revenue of ₹3,129.42 crore, a significant increase from ₹2,893.64 crore in the previous year. The company’s annual consolidated net profit rose to ₹647.51 crore, compared to ₹374.67 crore in the prior fiscal year. Basic earnings per share (EPS) for the year stood at ₹45.33.
Dividend and Shareholder Payouts
The Board of Directors has declared an interim dividend of ₹7.21 per fully paid-up equity share of Re. 1 each for the financial year 2026-27. Shareholders who are eligible to receive this dividend are those listed in the company’s records as of the record date, which is set for Friday, May 29, 2026. The payout is scheduled to be made to eligible shareholders on or before June 19, 2026.
Strategic Acquisitions and Business Updates
During the fiscal year, Eris completed several strategic milestones, including the acquisition of the remaining minority shares of Swiss Parenteral Limited, making it a wholly owned subsidiary. Additionally, the company acquired the Branded Probiotics Business from Velbiom Probiotics Private Limited for ₹50 crore on a slump sale basis, completed on March 31, 2026. These initiatives align with the company’s focus on long-term growth and market consolidation within the pharmaceutical sector.
Impact of Regulatory and Tax Changes
The company noted an exceptional impact of ₹17.24 crore on its financials due to the implementation of new labour codes in India, which affected gratuity and leave liabilities. Furthermore, the company successfully optimized its tax position by opting for the concessional tax regime for the upcoming financial year, resulting in a significant deferred tax credit of ₹150 crore recognized in the statement of profit and loss.
Source: BSE
